Pfizer partners with US biotech firm to develop treatment for hemophilia

December 8, 2014 9:11 PM

14 0

Following a series of past setbacks in the gene therapy space, Pfizer Incorporated has partnered with another US biotech firm, Spark Therapeutics, to develop effective gene therapy technology and a treatment for hemophilia – a congenital tendency to uncontrolled bleeding, usually affecting males and transmitted from mother to son.

A top UK gene therapy expert, Michael Linden has been contracted to lead Pfizer’s gene therapy research effort on a two-year secondment, and hopes of success are high considering the credentials of the persons and companies involved in this breakthrough effort. Linden is a professor from King’s Coll...

Read more

To category page